Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Tilting Capital plans reverse merger with ArcScan
Canadian venture group Tilting Capital said that it’s planning a reverse merger with Golden, Colo.-based ophthalmic imaging device developer ArcScan.
Tilting Capital said it agreed to put up about $7.2 million (Cdn $9.2 million) worth of its own stock, or 61.4 million shares, valued at 12¢ (Cdn 15¢) apiece, in a 1-for-1 trade with ArcScan stockowners. Read more
2. Thoratec touts less-invasive HeartMate 3 implantation
Thoratec revealed the 1st implantation of its next-generation HeartMate 3 implantable heart pump using a mini-thoracotomy approach.
The implantation, part of a European trial designed to examine less-invasive procedures such as hemi-sternotomy and left thoracotomy, was the 1st of a planned 10 surgeries, Pleasanton, Calif.-based Thoratec said. Read more
1. Procept BioRobotics closes $42m round for AquaBeam prostate device
Procept BioRobotics said that it closed on a $42 million round for its AquaBeam “waterjet ablation” device for treating prostate cancer.
Redwood Shores, Calif.-based Procept said the round was led by Novo Nordisk’s investment arm, Novo A/S, with new backer CPMG and existing investors also contributing. Read more
